Furthermore, our in vitro models of human CD34+ HPC-induced MK differentiation represent a tool to study the interactions of SARS-CoV-2 variants with specific hematopoietic target cells and to test new drugs preventing SARS-CoV-2 binding and subsequent infection of these cells. This evidence concerns the gene CD34 and infection.